Abstract:Chemokine receptor CCR2 is a member of the seven-transmembrane G-protein-coupled receptor superfamily, and is predominantly expressed on monocytes and macrophages. The interaction of the chemokine CCL2 with the CCR2 plays an important role in the recruitment of monocytes, natural killer cells, dendritic cells and T-lymphocytes. Recent studies have linked the CCL2/CCR2 axis to various inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, atherosclerosis, diabetes and even cancer. Thus, small molecule antagonists which can block the binding of CCR2 and CCL2 represent new therapeutic interventions of the inflammation-related diseases. By comprehensively analyzing the structures of the literature-reported potent CCR2 antagonists, we concluded a pharmacophore model for CCR2 inhibition, including a basic amino center, a hydrophobic aromatic ring on the right-hand side, and an amide group which serves as a hydrogen bond acceptor and a hydrogen bond donor. Then we performed the lead deconstruction and pharmacophore model-based privileged fragment reassembly strategy to discover new scaffold small molecule CCR2 inhibitors. The lead-like privileged scaffolds of alpha-alkyl-gamma-aminobutanamide and glycinamide were selected to combine with novel aromatic moiety and amide portion, delivering 3 classes of new structure CCR2 inhibitors. Total 11 compounds were designed and synthesized via a facile convergent synthetic procedure. The CCR2 antagonism activity evaluation revealed that N-(3-aminocyclopentane-carboxamido) methyl) benzamide was an active scaffold (exemplified by 1a, IC50= 25 nmol/L). The preliminary structure-activity relationship study indicated that the basic amino group and the lipophilic aliphatic moiety and small size aromatic group are important for the interaction with CCR2 protein. The replacement of the basic amino group with an amide would lead to the significant loss of the activity. This work provides a promising new structure CCR2 inhibitor and useful SAR conclusions which will promote the further development of CCR2 inhibitor into drug candidate.

Synthesis, Structure–Activity Relationship Studies, and ADMET Properties of 3‐aminocyclohex‐2‐en‐1‐ones As Chemokine Receptor 2 (CXCR2) Antagonists

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Discovery of 1,5-Dihydro-4<i>H</i>-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2

Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

Design, Synthesis, and Evaluation of Novel CXCR4 Antagonists Based on an Aminoquinoline Template.

Design, Synthesis, and Structure-Activity-relationship of a Novel Series of CXCR4 Antagonists.

Computational Analysis of the Structural Mechanism of Inhibition of Chemokine Receptor CXCR4 by Small Molecule Antagonists

Design and Synthesis of Tri‐substituted Chiral Pyrrolidin‐2‐one Derivatives As CCR4 Antagonists

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

Design, Syntheses, and Characterization of Piperazine Based Chemokine Receptor CCR5 Antagonists As Anti Prostate Cancer Agents.

Structural Optimization of Aminopyrimidine-Based CXCR4 Antagonists.

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

Structure-Based Development of Antagonists for Chemokine Receptor CXCR4

Design, Synthesis and SAR Study of Novel Trisubstituted Pyrimidine Amide Derivatives As CCR4 Antagonists

The Chemical Diversity and Structure-Based Evolution of Non-Peptide CXCR4 Antagonists with Diverse Therapeutic Potential.

Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy.

Structural insights into the activation and inhibition of CXC chemokine receptor 3

Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists.

Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2)

Quantitative structure–activity relationship study of nonpeptide antagonists of CXCR2 using stepwise multiple linear regression analysis